Stifel reiterates Compass Therapeutics stock rating on trial data By Investing.com

Compass Therapeutics reported mixed Phase 2/3 COMPANION-002 data: progression-free survival improved to 4.7 months versus 2.6 months for paclitaxel alone, but intention-to-treat overall survival was 8.9 months versus 9.4 months in the control arm. Stifel reiterated a Buy with a $12 target and William Blair reiterated Outperform, but crossover effects and unmet OS endpoints temper regulatory optimism. The stock trades at $5.03, and analysts’ targets range from $8 to $30.

Analysis

The market is likely underappreciating how asymmetric this setup is for CMPX: the data meaningfully derisks one tumor-control axis, but not the binary path to approval. In biotech, a strong PFS signal can support valuation only if the Street believes it translates into labelable clinical utility; here, the OS miss creates a credibility gap that may persist for months and keeps the stock hostage to regulatory interpretation rather than just clinical efficacy.

The real second-order issue is not the headline crossover story, but the probability that investors start discounting future datasets from the same program with a higher evidence hurdle. If management cannot present clean safety granularity and a coherent path to handling crossover, the market may treat any additional positives as “interesting but insufficient,” which caps upside even if the platform has broader value. That tends to compress multiple expansion in smaller-cap oncology names more than it impacts near-term trading volume.

Consensus seems to be splitting into a classic binary-biotech camp: bulls anchor on the PFS delta and price target dispersion, while bears focus on OS and approval risk. The contrarian read is that both can be right—this can still be a tradable stock without being a clean fundamental winner. With shares already up sharply over the past year, the more likely near-term reaction is volatility around the webcast and any FDA-facing commentary, not a straight-line rerating.

Competitively, the main beneficiaries are not named peers but other late-stage oncology programs with cleaner overall-survival narratives; capital may rotate toward names where the endpoint package is simpler to underwrite. For CMPX, the next few weeks matter more than the next few quarters: webcast detail, analyst model revisions, and any management guidance on regulatory interaction will determine whether this is a pause in a longer de-risking trend or the start of a multiple reset.

Key Decisions for Investors

• Trade CMPX tactically rather than structurally: buy a small starter position only on post-webcast weakness if management clarifies safety and crossover handling; target a 15-25% bounce, with a hard stop if the market interprets the disclosure as regulatory dilution.
• Use short-dated options around the webcast: sell straddles only if implied volatility is elevated and you are comfortable with binary event risk; otherwise, buy 1-2 month calls against a stock position to express upside while capping event risk.
• Pair trade: long higher-quality late-stage oncology names with cleaner OS packages, short CMPX into any strength if the market starts pricing the PFS result as approvable by itself; this expresses a relative-quality view rather than a pure biotech beta bet.
• If already long, trim into analyst-target-driven spikes and keep the remainder for a 60-90 day catalyst window; the OS overhang is likely to suppress multiple expansion until there is clearer FDA guidance.